IFN-beta twice a daily/Ribavirin combination therapy following PEG-IFN-alfa/Ribavirin therapy for chronic hepatitis C patients: efficacy and safety

IFN-beta twice a daily/Ribavirin combination therapy following PEG-IFN-alfa/Ribavirin therapy for chronic hepatitis C patients: efficacy and safety - IFN-beta twice a daily/Ribavirin combination therapy following PEG-IFN-alfa/Ribavirin therapy for chronic hepatitis C patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003549

Enrollment

Registered

2010-06-01

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

IFN-beta twice a daily/Ribavirin therapy following Peg-IFN-alfa/Ribavirin therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 chronic hepatitis C 2 Serogroup1 and high viral load patients

Exclusion criteria

Exclusion criteria: contraindication of IFN/Ribavirin tharapy

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026